The Impact of Opioid Use on Rural Communities and Effective Treatment Approaches and Recovery Supports (Part 2)
This webinar provides an overview on the impact of stimulant use on non-metropolitan rural communities.
The Substance Abuse and Mental Health Services Administration (SAMHSA) today released a new data report Lesbian, Gay, and Bisexual Behavioral Health
Results from the 2021 and 2022 National Surveys on Drug Use and Health, indicating that lesbian, gay, and bisexual adults are more likely than straight adults to use substances, experience mental health conditions including major depressive episodes, and experience serious thoughts of suicide.
The Impact of Opioid Use on Rural Communities and Effective Treatment Approaches and Recovery Supports (Part 1)
The Impact of Opioid Use on Rural Communities and Effective Treatment Approaches and Recovery Supports
SAMHSA has issued a new advisory on Identification and Management of Mental Health Symptoms and Conditions Associated with Long COVID
Long COVID can have devastating effects on the mental health of those who experience it due to social isolation, financial insecurity, chronic illness (both physical and psychological), caregiver burnout, and grief.
SAMHSA has issued a new Practical Guide for Implementing a Trauma-Informed Approach.
The primary goal of this guide is to expand the discussion presented in SAMHSA’s previous resources on trauma (Concept of Trauma and Trauma-Informed Care in Behavioral Health Services).
SAMHSA has issued a new Practical Guide for Implementing a Trauma-Informed Approach. Read More »
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD).
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder Read More »
Biden-Harris Administration Designates Fentanyl Combined with Xylazine as an Emerging Threat to the United States
Xylazine’s growing role in overdose deaths nationwide prompts Administration to make this designation for the first time in U.S. history
SAVE THE DATE
The Guam Behavioral Health and Wellness Center and Pacific Southwest Addiction Technology Transfer Center cordially invite you to save the date for Guam’s Fourth Annual Conference on Substance Use Disorders among Pacific Islanders.
FDA Approves First Over-the-Counter Naloxone Nasal Spray
Today, the U.S. Food and Drug Administration approved Narcan, 4 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription, use – the first naloxone product approved for use without a prescription.
FDA Approves First Over-the-Counter Naloxone Nasal Spray Read More »
Moving Beyond Change Efforts: Evidence and Action to Support and Affirm LGBTQI+ Youth
SAMHSA has issued a report on “Moving Beyond Change Efforts: Evidence and Action to Support and Affirm LGBTQI+ Youth.” This report provides behavioral health professionals, researchers, policymakers and other audiences with a comprehensive research overview and accurate information about effective and ineffective therapeutic practices related to youth of diverse sexual orientation and gender identity.
Moving Beyond Change Efforts: Evidence and Action to Support and Affirm LGBTQI+ Youth Read More »